Making the Difference in Cell and Gene Therapy
OXFORD BIOMEDICA SOLUTIONS
What We Do
At Oxford Biomedica Solutions, we partner with cell and gene therapy companies to provide innovative, end-to-end adeno-associated virus (AAV) platform process development and industry-leading manufacturing services to deliver life-saving and life-altering treatments to all.
HIGH YIELD HIGH QUALITY CONSISTENCY
What We Do
We offer thoughtful solutions leveraging our platform, experience, and technical expertise to ensure that all AAV products provide the
- high yield
- high quality
needed to be successful in the clinic.
EXCEPTIONAL VALUE EFFICIENCY INDUSTRY EXCELLENCE
What We Do
From construct and plasmid design through full-scale commercialization, we deliver
- exceptional value
- industry excellence
We are your trusted partners.
Technical Expertise in AAV Manufacturing
The Game Changing Engine—
Our proven platform provides high-yield, high-quality product, giving you more of what you need in smaller batch sizes
Our novel platform delivers
Achieved >1E15 vg/L bioreactor titer
accelerated cell and gene therapy product development
Across a range of serotypes and genes of interest
Achieved >1E17 vg of drug substance per 500L batch equivalent
high product quality
Demonstrated >90% full AAV vectors
Up to 2000L scale
- So you can stay ahead of the game.
Our highly accomplished team members bring expansive experiences, enabling us to offer
>1E15 vg/L bioreactor titer demonstrated in >10 serotypes and multiple genes of interest
>90% full AAV vector achieved
>1E17 vg of drug substance from a single 500L bioreactor lot
>45 methods developed for full vector characterization, quality control, and stability testing
6 successful IND/CTA submissions achieved
500 to 2000L scale confirmed in our platform process
Using our platform,
we have successfully—and repeatedly—delivered exceptional product quality for numerous constructs bearing different genomes and AAV serotypes across different production scales.Our Company
Maximizing Production and Quality of AAV Cell and Gene Therapies
Our platform process can
produce significantly higher titers of AAV drug substance per batch than traditional processes
conserve both time and resources
deliver the lowest cost per patient dose
Under these conditions, sufficient amounts of high-quality product are made in 500L batches, reducing or eliminating the need for pooling or scaling up.
Our proprietary process and patent families
ensure high product quality and yield, guaranteeing delivery of your product exactly as intended to patients.
Together, we can maximize the potential impact of AAV gene therapies on patients’ lives.
The ultimate benefit is
- accelerating your drug development timeline
- getting your product to clinic and market faster, while achieving product quality that will increase the probability of success for IND and BLA approval
- offering the best value economics in the industry
OXB Solutions is committed to ensuring that your process development and manufacturing needs are met through all stages of your AAV product drug development.
Life-saving and life-altering gene therapies for all.Fact Sheet
To learn more about our LentiVector® platform, visit Oxford Biomedica